COVID-19 and Behçet’s disease: clinical case series
| Autor: | Ainoa Ugarte, Pedro Juan Moreno, Marta Bodro, Richard Cervera, Sergi Amaro, Gerard Espinosa, Olga Araújo, Reinaldo Moreno |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
030203 arthritis & rheumatology
0301 basic medicine medicine.medical_specialty business.industry Immunology Disease Behcet's disease medicine.disease Rheumatology General Biochemistry Genetics and Molecular Biology 03 medical and health sciences Psoriatic arthritis 030104 developmental biology 0302 clinical medicine Rheumatoid arthritis Internal medicine Epidemiology medicine Immunology and Allergy business Rheumatism Systemic vasculitis |
| Zdroj: | Annals of the Rheumatic Diseases |
| ISSN: | 1468-2060 0003-4967 |
| DOI: | 10.1136/annrheumdis-2020-217778 |
| Popis: | We read with interest the study of Monti et al ,1 the first rheumatic disease cases with COVID-19. In detail, the authors described the clinical course of COVID-19 in a series of 11 patients with rheumatoid arthritis, one with psoriatic arthritis and one with spondyloarthritis treated with immunosuppressive targeted therapies. Here, we describe the main characteristics of four patients with Behcet’s disease (BD) with COVID-19. Data on patients with systemic autoimmune diseases with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are currently lacking. Data from the first 110 patients included in the COVID-19 Global Rheumatology Alliance and the European League Against Rheumatism (EULAR)–COVID-19 Database have been recently published.2 Here we describe, to our knowledge, the first single-centre experience of COVID-19 in patients who fulfilled the international criteria for BD,3 including clinical characteristics, antiviral and immunomodulatory treatment, and outcomes. All patients gave informed consent for publishing their clinical data. We used nasopharyngeal swab samples for all diagnoses, amplifying … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|